| [1] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2007 版)[J]. 中国癌症杂志,2007,17(5):410-428.
|
| [2] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J]. 中国癌症杂志,2015,25(9):692-754.
|
| [3] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J]. Lancet,2013,381(9869):805-816.
|
| [4] |
Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6935 women with early breast cancer [EB/OL]. [2016-02-03].http:/ /meetinglibrary.asco.org/content/112995-132.
|
| [5] |
LHRH-agonists in Early Breast Cancer Overview group, Cuzick J,Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials[J]. Lancet, 2007, 369(9574):1711-1723.
|
| [6] |
Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol,2011,12(7):631-641.
|
| [7] |
Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med,2014,371(2):107-118.
|
| [8] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J].N Engl J Med,2012,366(6):520-529.
|
| [9] |
Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study[J]. J Clin Oncol,2009,27(27):4530-4535.
|
| [10] |
Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant,formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment[J]. J Clin Oncol,2002,20(16):3396-3403.
|
| [11] |
Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy:results of a North American trial[J]. J Clin Oncol,2002,20(16):3386-3395.
|
| [12] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2013 版)[J]. 中国癌症杂志,2013,23(8):637-693.
|
| [13] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲtrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
|
| [14] |
Jiang ZF, Zhang QY, Shao ZM, et al. A phase Ⅲstudy of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the 500 mg dose [EB/OL]. [2016-02-01]. http:/ /m.cancerres.aacrjournals.org/content/75/9_Supplement/P1-13-07.short.
|
| [15] |
Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med,2015,372(10):923-932.
|
| [16] |
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31):3997-4013.
|
| [17] |
《乳腺癌HER2 检测指南(2014 版)》编写组. 乳腺癌HER2 检测指南(2014 版)[J]. 中华病理学杂志,2014,43(4):262-267.
|
| [18] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med,2001,344(11):783-792.
|
| [19] |
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱtrial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol,2005,23(19):4265-4274.
|
| [20] |
Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2):109-119.
|
| [21] |
Swain S,Kim SB,Cortes J,et al. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz),trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)[EB/OL]. [2016-02-01].https:/ /www. esmo. org/Conferences/Past-Conferences/ESMO-2014-Congress/News-Articles/Final-Overall-Survival-Analysis-from-the-CLEOPATRA-Study-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer.
|
| [22] |
Swain SM, Ewer MS, Cortes J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized,double-blind, placebo-controlled phase Ⅲ study [J]. Oncologist,2013,18(3):257-264.
|
| [23] |
Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2016,14(3):324-354.
|
| [24] |
Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲstudy of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J]. J Clin Oncol, 2006, 24(18): 2786-2792.
|
| [25] |
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲrandomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study[J]. J Clin Oncol,2011,29(3):264-271.
|
| [26] |
Schaller G, Bangemann N, Weber J, et al. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase Ⅱstudy of pre-treated metastatic breast cancer [EB/OL]. [2016-02-25].http:/ /meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/717.
|
| [27] |
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19):1783-1791.
|
| [28] |
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006,355(26):2733-2743.
|
| [29] |
von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study[J]. J Clin Oncol,2009,27(12):1999-2006.
|
| [30] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with erbB2-positive, trastuzumab-refractory metastatic breast cancer[J]. J Clin Oncol,2010,28(7):1124-1130.
|
| [31] |
Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study[J]. J Clin Oncol,2012,30(21):2585-2592.
|
| [32] |
Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K, et al. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy [J]. Cancer Chemother Pharmacol,2010,66(2):269-276.
|
| [33] |
Extra JM, Antoine EC, Vincent-Salomon A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study[J].Oncologist,2010,15(8):799-809.
|
| [34] |
Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med,2005,353(16):1673-1684.
|
| [35] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14):1273-1283.
|
| [36] |
Baselga J, Perez EA, Pienkowski T, et al. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer[J].Oncologist,2006,11 Suppl 1:4-12.
|
| [37] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol,2014,32(33):3744-3752.
|
| [38] |
Dang C, Fornier M, Sugarman S, et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer[J].J Clin Oncol,2008,26(8):1216-1222.
|
| [39] |
Tolaney SM, Barry WT, Dang CT, et al. A phase Ⅱstudy of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative,HER2-positive breast cancer (BC)[EB/OL]. [2016-02-23]. http:/ /cancerres.aacrjournals.org/content/73/24_Supplement/S1-04.
|
| [40] |
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised,open-label, multicentre,phase 3 trial[J]. Lancet,2012,379(9816):633-640.
|
| [41] |
Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial[J]. Lancet Oncol,2013,14(12):1183-1192.
|
| [42] |
Lisa AC, Donald AB,David O,et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase Ⅲtrial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer [EB/OL]. [2016-02-20]. http:/ /meetinglibrary. asco. org/content/108409-132.
|
| [43] |
Piccart-Gebhart M, Holmes AP,Baselga J,et al. First results from the phase Ⅲ ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D)comparing one year of anti-HER2 therapy with lapatinib alone (L),trastuzumab alone (T), their sequence (T→L), or their combination(T+L) in the adjuvant treatment of HER2-positive early breast cancer(EBC) [EB/OL]. [2016-02-03]. http:/ /meetinglibrary. asco. org/content/128258-144.
|
| [44] |
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol,2012,13(1):25-32.
|
| [45] |
Schneeweiss A,Chia S,Hegg R,et al. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy:an exploratory analysis of the TRYPHAENA study[J]. Breast Cancer Res,2014,16(4): R73.
|
| [46] |
Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer[J]. N Engl J Med, 2008, 358(16):1663-1671.
|
| [47] |
Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase Ⅲtrial evaluating the role of taxane and schedule in operable breast cancer [J]. J Clin Oncol,2015,33(21):2353-2360.
|
| [48] |
Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial[J].Lancet Oncol,2014,15(7):747-756.
|
| [49] |
Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱto Ⅲtriple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol,2015,33(1):13-21.
|
| [50] |
von Minckwitz G, Loibl S, Schneeweiss A, et al. Early survival analysis of the randomized phase Ⅱtrial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)[EB/OL]. [2016-02-03]. https:/ /www. sabcs. org/Portals/SABCS/Documents/SABCS-2015-Abstracts.pdf? v=5.
|
| [51] |
Sikov WM, Berry DA, Perou CM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer:Outcomes from CALGB 40603 (Alliance)[EB/OL]. [2016-02-03].http:/ /www.abstracts2view. com/sabcs15/view. php? nu=SABCS15L_1658.
|
| [52] |
O'shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase Ⅲstudy of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)[EB/OL]. [2016-02-03]. http:/ /meetinglibrary. asco. org/content/78038-102.
|
| [53] |
Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triplenegative breast cancer (CBCSG006): a randomised, open-label,multicentre, phase 3 trial[J]. Lancet Oncol,2015,16(4):436-446.
|
| [54] |
Hortobagyi GN, Lipton A, Chew HK, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial[EB/OL]. [2016-02-03]. http:/ /meetinglibrary.asco.org/content/129791-144.
|
| [55] |
Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial[J]. Clin Drug Investig, 2006, 26(6):315-322.
|
| [56] |
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind,multicenter,comparative trial[J]. Cancer,2003,98(8):1735-1744.
|
| [57] |
Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term followup of two randomized, placebo-controlled trials[J]. Cancer,2000,88(5):1082-1090.
|
| [58] |
Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study[J]. J Clin Oncol,2010,28(35):5132-5139.
|